Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexey Koval

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
Methods in Cell Biology|January 9, 2019
A high-throughput assay pipeline for specific targeting of frizzled GPCRs in cancerHolly V Shaw, Alexey Koval, Vladimir L Katanaev
Swiss Medical Weekly|October 4, 2019
Targeting the Wnt signalling pathway in cancer: prospects and perilsHolly V Shaw, Alexey Koval, Vladimir L Katanaev
Drug Discovery Today|December 16, 2021
Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD<sub>7</sub> in cancerYonika Larasati, Cédric Boudou, Alexey Koval, et al.
Plos One|June 27, 2014
Identification of novel elements of the Drosophila blisterome sheds light on potential pathological mechanisms of several human diseasesOleksii Bilousov, Alexey Koval, Amiran Keshelava, et al.
Analytical Biochemistry|October 24, 2009
Europium-labeled GTP as a general nonradioactive substitute for [(35)S]GTPgammaS in high-throughput G protein studiesAlexey Koval, Damir Kopein, Vladimir Purvanov, et al.
Biochemical Pharmacology|June 22, 2011
Yellow submarine of the Wnt/Frizzled signaling: submerging from the G protein harbor to the targetsAlexey Koval, Vladimir Purvanov, Diane Egger-Adam, et al.
Cancers|July 19, 2016
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersKamal Ahmed, Holly V Shaw, Alexey Koval, et al.
Handbook of Experimental Pharmacology|August 29, 2021
Mining Natural Compounds to Target WNT Signaling: Land and Sea TalesVladimir L Katanaev, Artem Blagodatski, Jiabin Xu, et al.
Frontiers in Pharmacology|November 17, 2022
Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitorsCédric Boudou, Luce Mattio, Alexey Koval, et al.
The International Journal of Biochemistry & Cell Biology|August 27, 2025
Syndecan-2 positively regulates Wnt/β-catenin signaling in breast cancer cellsLeyli Naraghi, Alexey Koval, Vladimir L Katanaev, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Methods in Cell Biology|January 9, 2019
A high-throughput assay pipeline for specific targeting of frizzled GPCRs in cancerHolly V Shaw, Alexey Koval, Vladimir L Katanaev
Swiss Medical Weekly|October 4, 2019
Targeting the Wnt signalling pathway in cancer: prospects and perilsHolly V Shaw, Alexey Koval, Vladimir L Katanaev
Drug Discovery Today|December 16, 2021
Unlocking the Wnt pathway: Therapeutic potential of selective targeting FZD<sub>7</sub> in cancerYonika Larasati, Cédric Boudou, Alexey Koval, et al.
Plos One|June 27, 2014
Identification of novel elements of the Drosophila blisterome sheds light on potential pathological mechanisms of several human diseasesOleksii Bilousov, Alexey Koval, Amiran Keshelava, et al.
Analytical Biochemistry|October 24, 2009
Europium-labeled GTP as a general nonradioactive substitute for [(35)S]GTPgammaS in high-throughput G protein studiesAlexey Koval, Damir Kopein, Vladimir Purvanov, et al.
Biochemical Pharmacology|June 22, 2011
Yellow submarine of the Wnt/Frizzled signaling: submerging from the G protein harbor to the targetsAlexey Koval, Vladimir Purvanov, Diane Egger-Adam, et al.
Cancers|July 19, 2016
A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersKamal Ahmed, Holly V Shaw, Alexey Koval, et al.
Handbook of Experimental Pharmacology|August 29, 2021
Mining Natural Compounds to Target WNT Signaling: Land and Sea TalesVladimir L Katanaev, Artem Blagodatski, Jiabin Xu, et al.
Frontiers in Pharmacology|November 17, 2022
Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitorsCédric Boudou, Luce Mattio, Alexey Koval, et al.
The International Journal of Biochemistry & Cell Biology|August 27, 2025
Syndecan-2 positively regulates Wnt/β-catenin signaling in breast cancer cellsLeyli Naraghi, Alexey Koval, Vladimir L Katanaev, et al.
Pageof 7